Podcasts

In our latest From Pathogen to Infectious Disease Diagnosis podcast, bioMérieux Chief Medical Officer Chuck Cooper, MD, discusses the burden of resistance, and insights on the company’s novel Vitek Compact Pro ID/AST system, which looks to identify infectious disease in a timely manner, and aid clinicians in diagnosing patients and streamlining antimicrobial treatment and avoiding severe complications such as sepsis.

MeMed CEO Eran Eden, PhD, discusses the MeMed BV test and how it can help make the distinction between the types of infections, aid in patient management, and reduce antimicrobial resistance.

This method represents a significant advancement in case management for this population. In our latest From Pathogen to Infectious Disease Diagnosis Podcast, Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, provides insights on its capabilities and how it can potentially aid clinicians in reducing antimicrobial resistance.

Jose Alexander, MD, ABMM, ABAIM, FCCM, CIC, ASCP, BCMAS, and his team discovered the klebsiella pneumoniae variant, KPC-31, in a patient by sequencing the entire genome through a series of different diagnostics, which not only led to identifying the strain, but to a greater understanding of its antimicrobial susceptibility.

Last year, several cases were identified in American patients traveling to Mexico to receive cosmetic surgery. The source of transmission was discovered, and one of the investigators, Sarah Bergbower DCLS, MS, MLS (ASCP)CM, discusses her part with 1 of the cases.

In the second episode with Michael Laposata, MD, PhD, he discusses how lab professionals can communicate with infectious disease clinicians, how AI can be used in diagnostics, and potential point-of-care diagnostic opportunities for the lab.

Here is our inaugural podcast with our host, Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc, who interviews guests on connecting lab professionals to clinicians and the intricacies of assays, the next generation of diagnostics, and the nuances of interpreting test results.

In the last segment of the series, Jones offered his insights for when he considers discharging patients.

In this conversation, Jones discussed concerns around empirical antimicrobial treatment and opportunities to narrow down therapies.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.

Bruce Jones, PharmD, FIDSA, BCPS provides commentary on treating challenging patients with comorbidities such as type 2 diabetes, higher BMI, and advanced age.

Christian Sandrock, MD, MPH, FCCP, highlights key takeaways on approaching treatment of antimicrobial resistant gram-negative infections as presented in updated IDSA guidelines and ID week 2023.

George Sakoulas, MD, provides key insights on the management of soft tissue infections including the role of single-dose agents and treating patients in an outpatient setting.

An expert in infectious diseases shares treatment considerations and clinical strategies for the management of community acquired pneumonia (CAP).

Collaboration and teamwork are essential components in addressing UTI management and antibiotic resistance, explains infectious disease clinical specialist Kim Leuthner, PharmD, FIDSA.

COVID-19 reshaped the landscape of urinary tract infections (UTIs). Explore the prevalence of resistant pathogens, the impact on infection prevention, and the changes in positive pathogens.

In this mini podcast, Kim Leuthner, PharmD, FIDSA, explores the challenges of choosing empirical therapy for complicated UTIs before culture results are available.

Recognizing high-risk patients is crucial for effective management of UTIs, explains Kim Leuthner, PharmD, FIDSA.

In this mini-podcast, infectious diseases clinical pharmacy specialist Bruce M. Jones, PharmD, FIDSA, BCPS, breaks down the “very straightforward criteria” he uses to decide whether a skin and soft tissue infection (SSTI) patient should be inpatient or outpatient.

In this podcast episode, Christian Sandrock, MD, MPH, FCCP, describes the need to make significant progress in antimicrobial stewardship.

Dr. Teena Chopra discusses the global need to do more to prevent healthcare-associated infections like C difficile in vulnerable patient populations.

What steps need taken to end viral hepatitis by 2030? “It all comes down to testing,” said Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

Listen to our interview with Sanofi vaccine expert Dr. Christopher Rizzo about what this preferential recommendation means, and why high-dose flu vaccines are needed for older adults.

Joined by Steven Wolfe, DO, MPH, and Stuart A Fisk, CRNP, of the Allegheny Health Network, we discuss the populations most at risk of HIV infection, as well as advice for making healthcare spaces more inclusive and accessible for LGBTQ+ people.

Although the development of antibiotics remains a challenge, there are some legislative strategies that could make it more attractive and get more players involved.

People who use drugs face obstacles, like homelessness and stigma, that hinder their access to healthcare. Dr. Brianna Norton opened the Montefiore-NYHRE Clinic, a first-of its kind academic medical center, to serve marginalized people holistically and respectfully.

In this latest episode of Contagion Community, we interview Dr. Jacinda Abdul-Mutakabbir about vaccine equality vs vaccine equity as well as her experience on a COVID-19 vaccine drive to increase vaccinations in communities of color.

In this first episode of Contagion Community, we interview vaccine research scientist Dr. Leonard Friedland about vaccination disparities in the US and around the world.

The Vanderbilt Professor of Preventive Medicine shares thoughts on the first potential COVID-19 vaccine, at a time of record new daily cases.

A glimpse into FDA advisor perspective just weeks before EUAs are anticipated to be sent.